DuChemBIO Co.,Ltd. (KOSDAQ:176750)
South Korea · Delayed Price · Currency is KRW 6,670.00
-80.00 (-1.19%)
At close: Aug 11, 2026
DuChemBIO Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Operating Revenue | 39,818 | 38,572 | 35,601 | 34,695 |
Other Revenue | -0 | -0 | - | -0 |
| 39,818 | 38,572 | 35,601 | 34,695 | |
Revenue Growth | 11.67% | 8.35% | 2.61% | - |
Cost of Revenue | 24,706 | 24,342 | 23,367 | 22,898 |
Gross Profit | 15,112 | 14,230 | 12,234 | 11,797 |
Selling, General & Admin | 5,514 | 5,430 | 5,548 | 5,087 |
Research & Development | 190.43 | 22.57 | - | 205.31 |
Amortization of Goodwill & Intangibles | 987.8 | 982.07 | 977.8 | 979.73 |
Operating Expenses | 7,082 | 6,787 | 7,158 | 6,541 |
Operating Income | 8,030 | 7,443 | 5,076 | 5,256 |
Interest Expense | -1,214 | -1,062 | -1,091 | -1,364 |
Interest & Investment Income | 266.48 | 221.64 | 89.64 | 90.89 |
Earnings From Equity Investments | 164.01 | -24.69 | 1,106 | -69.64 |
Currency Exchange Gain (Loss) | -7.87 | -4.77 | -34.84 | -7.99 |
Other Non Operating Income (Expenses) | -52.68 | -54.72 | 30.23 | 68.38 |
EBT Excluding Unusual Items | 7,185 | 6,519 | 5,177 | 3,974 |
Gain (Loss) on Sale of Investments | 207.24 | 207.24 | 387.82 | 92.13 |
Gain (Loss) on Sale of Assets | 3.56 | 2.85 | -0.18 | 16.28 |
Asset Writedown | -72.81 | -72.81 | - | -30.7 |
Pretax Income | 7,323 | 6,656 | 5,564 | 4,052 |
Income Tax Expense | 348.9 | 176.72 | -2,429 | 51.23 |
Net Income | 6,975 | 6,480 | 7,994 | 4,001 |
Net Income to Common | 6,975 | 6,480 | 7,994 | 4,001 |
Net Income Growth | -8.34% | -18.94% | 99.82% | - |
Shares Outstanding (Basic) | 28 | 28 | 27 | 27 |
Shares Outstanding (Diluted) | 28 | 28 | 27 | 27 |
Shares Change | 2.88% | 5.75% | 0.43% | - |
EPS (Basic) | 247.62 | 228.61 | 297.54 | 149.54 |
EPS (Diluted) | 246.97 | 228.00 | 297.54 | 149.54 |
EPS Growth | -10.93% | -23.37% | 98.97% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Free Cash Flow | 10,699 | 9,074 | 5,440 | 7,293 |
Free Cash Flow Per Share | 378.94 | 319.36 | 202.48 | 272.63 |
Gross Margin | 37.95% | 36.89% | 34.36% | 34.00% |
Operating Margin | 20.17% | 19.30% | 14.26% | 15.15% |
Profit Margin | 17.52% | 16.80% | 22.45% | 11.53% |
Free Cash Flow Margin | 26.87% | 23.52% | 15.28% | 21.02% |
EBITDA | 15,817 | 14,313 | 10,641 | 11,016 |
EBITDA Margin | 39.72% | 37.11% | 29.89% | 31.75% |
D&A For EBITDA | 7,787 | 6,870 | 5,565 | 5,760 |
EBIT | 8,030 | 7,443 | 5,076 | 5,256 |
EBIT Margin | 20.17% | 19.30% | 14.26% | 15.15% |
Effective Tax Rate | 4.76% | 2.66% | - | 1.26% |
Advertising Expenses | - | 172.04 | 76.18 | 62.35 |